Preventing and repairing gut injury after bone marrow transplant
Cellular and Molecular Studies of Bone Marrow Transplant
Lab discoveries about how the immune system damages gut stem cells are being turned into new treatments to help people with severe gut graft-versus-host disease after an allogeneic bone marrow transplant.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11191449 on NIH RePORTER |
What this research studies
You would be part of a program that studies why the intestine is so badly harmed by immune attacks after a donor bone marrow transplant and how to help it heal. Researchers are focusing on intestinal stem cells and key molecules like the mitochondrial enzyme SDHA and the signaling protein RIPK1 to understand how damage happens and how to restore regeneration. The work combines lab models with analysis of patient gut biopsies and shared clinical cores. Promising lab findings are being moved into Phase 2 clinical trials that patients may join to test therapies aimed at protecting or repairing the gut.
Who could benefit from this research
Good fit: Ideal candidates are people who have had an allogeneic hematopoietic cell (bone marrow) transplant and are developing or have acute gastrointestinal graft-versus-host disease or are at high risk for it.
Not a fit: People without GI involvement after transplant, those with unrelated medical conditions, or patients who do not meet trial safety criteria may not benefit or be eligible.
Why it matters
Potential benefit: If successful, this work could reduce severe gut GVHD, lower deaths after transplant, and allow more patients to safely receive curative allogeneic transplants.
How similar studies have performed: Related laboratory studies and early-phase clinical work have shown some promising approaches to protect gut stem cells, but effective treatments for steroid-resistant GI GVHD remain limited.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Ferrara, James L. M. — Icahn School of Medicine at Mount Sinai
- Study coordinator: Ferrara, James L. M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.